By Gimmy Chen – It’s not big news that the life sciences and pharmaceutical industries are data-intensive but the the scale and scope of data analytics may still surprise people. The data volumes are immense. Data analytics is central to their main strategic and profit-making workloads.
Read More
By Art Gross – Healthcare businesses are increasingly reliant on technology to manage patient information, conduct financial transactions, and communicate with staff and patients. While technology has many benefits, it also presents significant risks, including the threat of cyberattacks.
By Rachel Nelson & Kathryn Marchesini – We often get asked about how ONC’s information blocking regulations and HHS’ Office for Civil Rights’ HIPAA Privacy, Security, and Breach Notification Rules interact with one another. To help clarify, ONC just released a few new information blocking FAQs that illustrate how the federal regulations interact.
By Katie Brenneman – To be sure, telehealth did not begin with the COVID-19 pandemic, nor will it end with it. Indeed, virtual patient care has been evolving for years, emerging alongside the ascendency of the digital revolution in other domains, from shopping to education.
By Treece Efird – The foundation of all electronic communications in healthcare is a robust and dependable data network. It is the fundamental requirement for electronic medical records, imaging, scheduling, billing, medication dispensing, and financial reimbursement.
By Robert L. Murry PhD MD FAAFP – A survey published by the American Medical Association last year reveals that patients are very concerned about the privacy of their medical information, perhaps more concerned than most physicians and practices are aware.
By David Burda – To answer the question in the headline, which I haven’t seen anywhere yet, is yes. Yes they did. That’s according to the latest annual March report to Congress from the Medicare Payment Advisory Commission, or MedPAC.
By Devin Partida – IT professionals in every sector have a duty to accelerate technological innovation. Medtech is a unique industry rife with outdated tools while being the most desperate for advancement to meet a growing population’s increasingly complex health needs.
By Tom Dorsett – As of April 2023, the FDA has approved the use of 40 “biosimilars”, which are a less expensive version of an advanced “biologic” medication. The rise of biosimilars is a major source of excitement as a way to control rising drug costs. But is the fervor warranted?